Study summary · research use only
Development of Cagrilintide, a Long-Acting Amylin Analogue
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This paper describes the development of cagrilintide, a stable, lipidated long-acting amylin analogue, addressing amylin's high propensity to form amyloid fibrils, which complicates drug design. Species is not specified for the structure-activity work described. The authors summarize structure-activity efforts leading to selection of cagrilintide (compound 23) for clinical development targeting obesity, contrasting it with the amylin analogue pramlintide, which requires three daily injections due to its short half-life. The abstract states cagrilintide is in clinical trial and has been associated with weight loss when dosed alone or together with the GLP-1 analogue semaglutide.
Abstract
A hallmark of the pancreatic hormone amylin is its high propensity toward the formation of amyloid fibrils, which makes it a challenging drug design effort. The amylin analogue pramlintide is commercially available for diabetes treatment as an adjunct to insulin therapy but requires three daily injections due to its short half-life. We report here the development of the stable, lipidated long-acting amylin analogue cagrilintide (23) and some of the structure-activity efforts that led to the selection of this analogue for clinical development with obesity as an indication. Cagrilintide is currently in clinical trial and has induced significant weight loss when dosed alone or in combination with the GLP-1 analogue semaglutide.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.